The first patient in cohort 4 has been dosed in the ongoing phase 1 OPTIC trial of ADVM-022, according to a press release from Adverum Biotechnologies.
Nine patients with wet age-related macular degeneration will receive a single intravitreal injection of ADVM-022 at a dose of 6 × 1011 vg/eye as well as a subsequent steroid eye drop prophylaxis for 6 weeks.
“We believe that utilizing the higher dose of ADVM-022 with the use of steroid eye drop prophylaxis will further support that our gene therapy candidate, ADVM-022, has the potential (Read more...)
Uncategorized